Compare EchoStar Corporation Common Stock (ECHO) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EchoStar Corporation Common Stock vs Natera Inc. Common Stock — how do they compare? EchoStar Corporation Common Stock trades at $86.94 (market cap $26.63B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 2.1× EchoStar Corporation Common Stock's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, EchoStar Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold EchoStar Corporation Common Stock for 6 Days and Natera Inc. Common Stock for 0 Days on average.
| ECHO | NTRA | |
|---|---|---|
Market Cap | $26.63B | $57.03B |
Volume | 2,918,300 | 1,131,157 |
Sector | Media | Health |
52-Week High | $141.80 | $425.64 |
52-Week Low | $66.93 | $179.42 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $43.68B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECHO trades at $91.56, down 3.72% over 24 hours, with a neutral technical signal and mixed earnings history including a significant Q2 2026 beat. The company reported a net loss of $14.50 billion in 2025, with negative cash flows, though revenue remains substantial at $15.00 billion. Recent news highlights institutional investments and a strategic partnership with United Airlines for in-flight streaming.
Analyst consensus is strongly bullish with a $134.00 price target, but high risks stem from persistent losses, negative cash flow, and the Hughes unit's bankruptcy. The stock's appeal hinges on turnaround execution and debt reduction efforts outweighing fundamental weaknesses.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About EchoStar Corporation Common Stock
EchoStar provides satellite communications and connectivity services. Its businesses support broadband, enterprise, government, and consumer communications needs.
Read more on ECHO →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
